Amgen Inc Data Scientist Interview: Questions & Prep (2026)

Amgen is one of the world's largest independent biotechnology companies, with medicines spanning oncology, cardiology, nephrology, and rare diseases. Data Scientists at Amgen work on problems that directly touch drug discovery, clinical trial analytics, real-world evidence (RWE), biomarker research, and commercial forecasting.

As of July 2026, Amgen has 89 open Data Scientist roles tracked by knok's job radar. The broader Data Scientist market in India stands at 937 active openings, with Bangalore leading at 166 roles, followed by Delhi at 46 and Hyderabad at 27. This makes Amgen one of the more active biotech hirers for data science talent in India right now.

Salary ranges for Data Scientists in India (from knok data):

Candidates report that the process typically includes a recruiter screen, a technical assessment or take-home case study, and one or more panel rounds with data science peers and cross-functional stakeholders from clinical or commercial teams. The process rewards both statistical depth and the ability to explain findings clearly to non-technical audiences.

These questions are drawn from candidate reports and reflect Amgen's focus on biomedical data, rigorous modelling, and cross-functional communication. Prepare a concrete story for each.

1. Walk us through a machine learning model you built end-to-end. What data quality challenges did you face and how did you resolve them?

1. How would you design an analysis to compare treatment effectiveness across patient subgroups in a clinical dataset?

1. Amgen works with genomic, proteomic, and clinical trial data. What hands-on experience do you have with high-dimensional biological or structured clinical datasets?

1. Your model performs well on training data but weaker on the validation set. How do you diagnose and address this?

1. How do you handle severe class imbalance in a patient outcome prediction model, for example when the positive class is a rare adverse event?

1. Describe a time you had to explain a counterintuitive or complex data finding to a non-technical audience such as a clinical team or business leadership. What did you do?

1. What is your experience with survival analysis or time-to-event modelling? Walk us through a real use case.

1. How would you validate a predictive model intended to influence decisions in a regulated healthcare or pharma environment?

1. Have you applied causal inference methods such as propensity score matching or difference-in-differences? Describe the problem and your approach.

1. Amgen teams use both Python and R. Which would you prefer for pharmacokinetics or dose-response analysis, and why?

1. How do you ensure reproducibility and auditability in your analysis pipelines?

1. Tell us about a project where your model or analysis directly changed a business or scientific decision. What was the outcome?

Q: Walk us through a machine learning model you built end-to-end. What data challenges did you face?

*Situation:* At a healthtech startup, our team wanted to predict patient no-shows for outpatient clinics using appointment history and demographic data.

*Task:* My responsibility was to build a reliable classifier and prepare it for deployment within one quarter.

*Action:* I started with exploratory analysis and discovered that a large portion of our historical records had been duplicated due to a recent system migration. I cleaned and deduped the dataset, then engineered features like appointment lead time, day of week, and prior no-show history. I compared logistic regression, gradient boosting, and a simple feedforward network using stratified cross-validation to account for seasonal patterns. Every preprocessing step was version-controlled and documented in a shared notebook.

*Result:* The gradient boosting model was selected and deployed. The clinic team described it as the first automated tool they had for proactive appointment reminders, and within the first month they reported a noticeable drop in unfilled slots.

---

Q: How do you handle severe class imbalance in a patient outcome prediction model?

*Situation:* During an internship with a hospital analytics team, I worked on predicting a rare post-surgical complication where the positive class made up a very small share of all cases.

*Task:* I needed a model that would flag high-risk patients reliably without generating so many false positives that the clinical team would stop trusting the alerts.

*Action:* I tested three approaches: oversampling the minority class with SMOTE, adjusting class weights in the model, and tuning the decision threshold separately after training. I evaluated each approach using precision-recall curves rather than accuracy, and held out a time-based test set to avoid data leakage. I presented the sensitivity versus false positive rate tradeoff to the clinical lead so they could pick an operating point that matched their workflow capacity.

*Result:* The team chose a threshold that maximised sensitivity at a false positive rate they felt was manageable. The model went into a pilot and clinicians said it surfaced cases they would otherwise have caught only at discharge.

---

Q: Describe a time you explained a counterintuitive finding to a non-technical audience.

*Situation:* At my previous company, our data showed that customers receiving more frequent promotional emails had lower conversion rates than those receiving fewer.

*Task:* I needed to present this to marketing leadership, who had been pushing for higher email frequency based on intuition and past practice.

*Action:* Instead of leading with statistical tests, I built a simple visual: two line charts showing conversion rate against email frequency for two customer segments. I used plain language: 'customers receiving more than four emails a week are tuning us out.' I also ran a cohort analysis across regions and product lines to preempt the 'but our segment is different' objection before it came up.

*Result:* The team reduced email frequency for the high-contact group in a controlled test. That test confirmed the finding and the team adopted a new sending policy based on the results.

Use STAR for every behavioural question. Cover the Situation (one or two sentences of context), Task (what you were responsible for), Action (what you specifically did, step by step), and Result (what happened and what you learned). Keep Situation and Task brief. Spend most of your time on Action and Result.

For technical design questions, use 'Problem, Approach, Tradeoff.' Restate the problem in your own words first so the interviewer knows you understood it correctly. Then describe your approach and the alternatives you considered. End with the tradeoff you made and why. This signals engineering judgment, not just textbook recall.

For open-ended case questions, think out loud. Amgen interviewers typically want to see your reasoning process, not just a correct final answer. Ask a clarifying question first, state your assumptions clearly, then walk through your logic step by step. Invite feedback at natural pauses.

Quantify results where you can, but be honest about what you measured. If you do not have a precise figure, say 'the team reported a meaningful improvement' rather than inventing a number. Amgen values scientific integrity, and that standard extends to how you describe your own work.

Domain awareness. You do not need a biology PhD, but you should understand why biomedical data is different: smaller sample sizes, regulatory requirements, complex missing data patterns in clinical records, and the high cost of a false negative in patient safety contexts. Read about Amgen's therapeutic areas and recent pipeline updates before your interview.

Statistical rigour. Candidates report that Amgen interviewers probe deeper than surface-level ML. Expect questions on experimental design, hypothesis testing, confidence intervals, and model validation strategies that would hold up in a regulated environment. Comfort with survival analysis and Bayesian methods is a meaningful advantage.

Cross-functional communication. Data Scientists at Amgen frequently present to clinical researchers, commercial teams, and senior leadership. Interviewers want concrete evidence that you can translate a complex finding into a clear, actionable message for someone who does not know statistics.

Reproducibility and data engineering habits. Version control, pipeline documentation, and audit trails matter more at a pharma company than at a typical startup. Be ready to discuss how you make your work reproducible and how you would defend your analysis to a regulatory auditor.

Curiosity and ownership. Amgen interviewers typically look for candidates who go beyond the immediate ask. Demonstrate that you asked 'why does this matter?' and that you followed up after delivering an analysis to see what actually happened.

Two to three weeks out

Read Amgen's recent pipeline news and any publicly available research publications linked from their website. Note which therapeutic areas are active: oncology, cardiometabolic disease, rare disease, and inflammation. Understand what 'real-world evidence' means in a pharma context and how it differs from randomised controlled trial data.

Refresh your statistics fundamentals: survival analysis, mixed-effects models, Bayesian inference, and multiple testing corrections. These topics appear more often in biotech data science interviews than in standard product or tech analytics roles.

One week out

Prepare five to six STAR stories covering: a model you built end-to-end, a time you dealt with messy or incomplete data, a time you influenced a business or scientific decision, a time you disagreed with a stakeholder, and a project where reproducibility was a priority.

Practise coding in Python and R. In Python, brush up on pandas, scikit-learn, and the lifelines library for survival analysis. In R, review tidyverse and the survival package. Also practise SQL for data extraction and transformation tasks.

Two to three days out

Do a mock technical interview with a peer. Practise explaining a model or statistical concept in plain language, as if the listener has no statistics background.

Prepare two or three questions for your interviewers. Questions about how the data science team collaborates with clinical or medical affairs functions tend to resonate well at Amgen.

The day before

Review your STAR stories once more. Candidates report that Amgen panel rounds can run two to three hours, so rest well and pace yourself through each section.

Treating it like a product analytics interview. Amgen is a regulated, science-first company. Answers focused only on A/B tests and conversion funnels miss the mark. Frame your experience in terms of rigour, reproducibility, and impact on research or patient outcomes.

Skipping domain context. Saying 'I would build a classifier' without acknowledging the stakes of a wrong prediction in a clinical setting signals a lack of domain awareness. Connect your technical choices to the real-world consequences in healthcare.

Overstating model performance. Amgen teams value scientific honesty. If your model had limitations, say so and explain how you communicated them. Interviewers are more impressed by 'here is what the model cannot do and why' than by an unexplained perfect result.

Underestimating the communication question. Many candidates prepare well for coding and statistics but underestimate how often interviewers ask 'how did you explain this to a non-technical stakeholder?' Prepare a concrete story and practise delivering it out loud.

Asking no questions at the end. Candidates who ask nothing typically come across as disengaged. Prepare genuine questions about the team's current research focus, their data infrastructure, or how they measure the impact of data science work.

Rushing the take-home exercise. Candidates report that Amgen rewards clear thinking and well-documented code over a complex but opaque solution. Write comments, state your assumptions explicitly, and present a clean, honest conclusion.